Day: November 15, 2024

PRESS RELEASENovember 15, 2024 INFORMATION ON THE DATE OF THE NEXT ANNUAL GENERAL MEETING OF RENAULT S.A. Boulogne-Billancourt, November 15, 2024 – Renault S.A. informs its shareholders that the next Annual General Meeting is scheduled on Wednesday, April 30th, 2025. This date will be confirmed by the Company’s Board of Directors which, in February 2025, will convene this Annual General Meeting. The schedule of the Company’s upcoming financial publications is available on the website: https://www.renaultgroup.com/en/. RENAULT GROUPINVESTOR RELATIONS Philippine DE SCHONENphilippine.de-schonen@renault.com+33 (0)6 13 45 68 39 RENAULT GROUP PRESS CONTACT Valérie GILLOT +33 6 83 92 92 96valerie.gillot@renault.com Rié YAMANE +33 6 03 16 35 20rie.yamane@renault.com About Renault Group Renault Group is at the forefront of...

Significantly greater mean declines in HBsAg levels (p

Ipsen presents 3 late-breaking presentations and 8 abstracts across rare cholestatic liver disease portfolio at AASLD 2024 Iqirvo approved for use in the U.S. in June 2024, in the E.U. in September 2024 and in the U.K. in October 2024 PARIS, FRANCE, 15 November 2024 Ipsen (Euronext: IPN; ADR: IPSEY) announced today late-breaking data for Iqirvo® (elafibranor 80 mg tablets) from an interim analysis of the ongoing open-label extension of the Phase III ELATIVE® study at the American Association for the Study of Liver Disease (AASLD) congress. The late-breaking presentations (Abstract #5041 and Abstract #5042) report on biomarkers of cholestasis, stabilization of surrogate markers of liver fibrosis and moderate-to-severe pruritus data for up to three years in Iqirvo-treated patients. Additionally, exploratory endpoints in fatigue and sleep...

— Over 40% of participants treated with EFX 50mg for 96 weeks, compared with 0% for placebo, showed regression of liver fibrosis by all of three orthogonal measures: (1) ≥1-stage fibrosis improvement by NASH-CRN stage (conventional histopathology), (2) 30% reduction of liver stiffness by FibroScan® (imaging fibrosis biomarker), and (3) 0.5 point decrease in ELFTM score (serum fibrosis biomarker) – — Analysis of biopsies by AI-based Digital Pathology (qFibrosis®, Histoindex) corroborated the extent of improvement in fibrosis observed with conventional histopathology after 24 and 96 weeks of EFX treatment, including statistically significant reductions in fibrosis within the perisinusoidal and periportal zones of the liver – — 30% of participants receiving EFX 50mg for 96 weeks, compared to 0% for placebo, had almost complete...

BOSTON, Nov. 15, 2024 (GLOBE NEWSWIRE) — Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today presented three poster presentations supporting the combination of bemnifosbuvir and ruzasvir as a potential treatment for hepatitis C virus (HCV). The combination of bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an NS5A inhibitor, is in Phase 2 development for the treatment of HCV. These data are being presented at the American Association for the Study of Liver Diseases’ (AASLD) The Liver Meeting 2024, being held from November 15-19, 2024 in San Diego, CA. “These important data presented today at The Liver Meeting add to the growing body of evidence supporting the...

Weekly subcutaneous doses of pemvidutide resulted in robust reductions in cardio-inflammatory, hepato-inflammatory and atherosclerotic lipids Findings support the potential benefit of pemvidutide on co-morbidities of metabolic dysfunction-associated steatohepatitis (MASH), including atherosclerosis, heart disease and metabolic syndrome Pemvidutide is currently being evaluated in IMPACT, the Phase 2b trial in subjects with MASH; data readout expected in Q2 2025 GAITHERSBURG, Md., Nov. 15, 2024 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today presented new data from its 12-week Phase 1b trial of pemvidutide in metabolic dysfunction-associated steatotic liver disease (MASLD) at The Liver Meeting® of the American Association for the Study of Liver Diseases. The data showed reductions...

15th November 2024 | SAINT HELIER, Jersey—CoinShares International Limited (“CoinShares” or the “Company”) (Nasdaq Stockholm: CS; US OTCQX: CNSRF), the leading European investment firm specialising in digital assets, today highlighted its latest successful business transformation with Valkyrie (now CoinShares Valkyrie), its U.S.-based ETF business acquired in March 2024. Since the acquisition, Valkyrie’s assets under management (AUM) have grown significantly from approximately $110 million to over $1 billion, demonstrating CoinShares’ ability to identify and develop valuable market opportunities. This transformation is the latest example in CoinShares’ series of successful strategic acquisitions and turnarounds. The Company has established a proven model of identifying businesses with strong fundamentals...